Table 2.
Stratified analysis of pooled hazard ratio risks of D-dimer in LC patients.
| Stratified | Pooled HR | Heterogenety | Meta regression |
|---|---|---|---|
| analysis | (95% CI) | (P-value) | |
| Public year | 0.794 | ||
| After 2015 | 1.70 [1.38–2.10] | Q = 54.51, P < 0.01, I2 = 78.0% |
|
| Before 2015 | 1.67 (1.22–2.29) | Q = 16.95, P < 0.01, I2 = 71.0% |
|
| Country | 0.121 | ||
| China | 1.44 [1.19–1.75] | Q = 38.22, P < 0.01, I2 = 74.0% |
|
| Non-China | 2.22 [1.58–3.13] | Q = 30.27, P < 0.01, I2 = 77.0% |
|
| Population | 0.683 | ||
| SCLC | 1.86 [1.33–2.61] | Q = 40.12, P < 0.01, I2 = 85.0% |
|
| NSCLC | 1.60 [1.33–1.92] | Q = 31.52, P < 0.01, I2 = 65.0% |
|
| Follow-up months | 0.519 | ||
| ≥60 months | 1.89 [1.42–2.51] | Q = 49.03, P < 0.01, I2 = 82.0% |
|
| <60 months | 1.52 [1.26–1.83] | Q = 22.44, P < 0.01, I2 = 64.0% |
|
| Design | 0.074 | ||
| RS | 1.21 [0.96–1.53] | Q = 13.8, P < 0.01, I2 = 78.0% |
|
| PCS | 1.93 [1.57–2.37] | Q = 49.21, P < 0.01, I2 = 72.0% |
|
| Quality Score | 0.537 | ||
| <6 | 1.55 [1.15–2.09] | Q = 33.88, P < 0.01, I2 = 85.0% |
|
| ≥6 | 1.74 [1.43–2.12] | Q = 34.18, P < 0.01, I2 = 65.0% |
|
| Stage | <0.001 | ||
| NALC | 1.29 [1.15–1.44] | Q = 26.23, P < 0.01, I2 = 58.0% |
|
| ALC | 2.91 [2.24–3.78] | Q = 6.38, P = 0.38, I2 = 6.0% |
|
SCLC, small cell lung cancer; NSCLC, non-small-cell lung cancer; LC, lung cancer; NALC, non-advanced lung cancer; ALC, advanced lung cancer; RS, retrospecitive study; PCS, prospective cohort study; HR, hazard ratio.